Outlook Therapeutics Q2 2024 Adj EPS $(1.55) Misses $(0.85) Estimate
Author: Benzinga Newsdesk | May 15, 2024 05:02pm
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(1.55) per share which missed the analyst consensus estimate of $(0.85) by 82.35 percent.